Wednesday 25 November 2015

Even after a raise it's important to manage your money! (Five moves to make after getting a raise)

Monday 23 November 2015

Interesting article!

Light therapy may ease depression, not just winter blues

                   
 

(Reuters Health) - Light therapy, long used to help improve mood in people who get the blues when days are darker and shorter, can also treat non-seasonal depression, a small Canadian study suggests.
Depression is one of the most common mental health disorders and a leading cause of disability and reduced quality of life worldwide, the researchers note in JAMA Psychiatry.

While many people with depression may be helped by medication or psychotherapy, these options don’t work for everybody and some patients don’t stick with treatment due to side effects or challenges related to access or affordability.

“This study is the first to show that light therapy alone is effective versus a placebo, and the first to compare combination light and drug to light alone,” said lead study author Dr. Raymond Lam of the University of British Columbia.

“The combination of light therapy and antidepressant was the most effective,” Lam added by email. “However, some people may prefer to try a non-medication treatment first, and may elect to start with light therapy.”

To test the effectiveness of light therapy for non-seasonal depression, Lam and colleagues randomly assigned 122 patients to one of four groups for eight weeks: only medication, only light, a combination of drugs and light therapy, or a control group that received no active treatments.

The active treatments in the study included a daily 20-milligram dose of fluoxetine (Prozac) and daily exposure to a fluorescent light box for 30 minutes after waking up each morning.

Researchers gave people assigned only light therapy a placebo, or inactive pill, and they provided participants assigned only to drug treatment with an inactive device instead of a working light box. The control group received both the placebo pill and the inactive device.

At the start of the study, researchers used a standard questionnaire to assess the severity of depression by asking participants about sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lack of energy, inability to feel, and pessimistic or suicidal thoughts.

The highest score is 60, indicating the most severe depression. On average, participants had scores of about 26 or 27 at the start of the study, pointing to moderate depression.

After eight weeks, the group receiving both medication and light therapy had the biggest average drop in depression scores, with a 16.9 point decline.

People who got only light therapy had an average 13.4 point decline in depression scores, while people who had only medication experienced an 8.8 point drop and the control group getting only inactive treatments had a 6.5 point decrease.

While the exact reason light therapy might ease depression is unknown, it may have worked by helping to reset the biological clock in the brain, or circadian rhythms, the researchers hypothesized.
One shortcoming of the study is that researchers lacked data on how much exposure people had to natural light during the study, the authors acknowledge. It’s also possible that a higher dose of medication or light therapy might have made a bigger impact.

Normally, if an antidepressant doesn’t work in a low dose, clinicians will gradually increase the dose to help achieve the right amount of medicine to ease symptoms, noted Dr. Teodor Postolache, a psychiatry researcher at the University of Maryland School of Medicine in Baltimore who wasn’t involved in the study.

“Light treatment could be an adequate agent that in combination with medications may make the response to treatment more complete,” Postolache said by email. “However, I would emphasize that patients should not buy a light treatment device and start adding it to their antidepressants on their own.”

The best time in the course of treatment to consider light therapy may also depend on the severity of symptoms, said Sue Penckofer, a researcher at Loyola University in Chicago who wasn’t involved in the study.

“If somebody has more mild depression they might try light therapy first, but if they have more moderate or serious depression medication might be recommended instead,” Penckofer said.
SOURCE: http://bit.ly/1MppYER JAMA Psychiatry, online November 18, 2015.

Saturday 21 November 2015

Good turnout!

Mergers & Acquisitions conference in Minneapolis draws record turnout

 
M&A conference draws record turnout
 
“A year from now, we are going to call 2014 and 2015 the golden age of M&A.”
 
That’s the word from Sima Griffith, managing principal for Minneapolis-based ­Aethlon Capital, who has been raising capital and completing mergers and acquisitions for more than 25 years. She made the comment while attending law firm Faegre Baker Daniels’ 10th annual mergers and acquisitions conference Wednesday at the Marriott City Center.
 
The event is one of the premier M&A conferences in the country. This year, the conference drew nearly 450 attendees, its biggest turnout ever, with participants coming from as far away as China, Germany, Canada and London.
 
Featured were 10 panel discussions ranging from case studies on natural and organics food company acquisitions, including the General Mills/Annie’s and Hormel Foods/Applegate deals, to H.B. Fuller’s transformational $230 million deal involving China’s Tonsan Adhesives. The agenda also included breakout discussions on such topics as current deal activity.
Much of the discussion around the food deals was how much thought the big companies put into preserving the culture of the mission-driven companies they acquired, described by one General Mills executive as bringing “the power of the big to the small.”
 
One takeaway from the H.B. Fuller session was the importance of face-to-face negotiations, especially when the market has dictated that deals get done faster than ever with fewer and fewer in-person meetings.
 
One topic that arose early and was repeated consistently throughout the day’s sessions is that it remains a seller’s market in M&A. While it remains prime-time to be a quality seller in this market, the end may be in sight.
 
The first panel concluded with predictions of what 2016 will bring. How far and how fast M&A activity slides from peak activity will depend in large part on private equity firms and increasingly family offices that have been key contributors to this golden age of M&A activity.
 
Private equity firms now own about 10,000 companies, and family offices at investment banks have become increasingly aggressive in making deals.
 
Private equity firms have on average held their companies for five to six years, but those holding periods have been coming down. Some panel members told anecdotes about the firms flipping investments in as little as 18 months.
 
Meanwhile, family offices have been winning bids by selling themselves as longer-term investors, panelists said.
Patrick Kennedy

Wednesday 18 November 2015

How the world's 20 largest economies help, and hinder, climate protection

REUTERS
Collectively the G20 contributes about 85 percent of the world’s gross domestic product, conducts 80 percent of overall world trade, contains 64 percent of the world’s population – and, according to the report, creates 74 percent of global GHG output.
      
Just ahead of the G20 summit in Turkey that begins on Sunday, two new reports paint intriguing – and very different – pictures of how the world’s largest economies are acting on global warming.
From Climate Transparency comes a finding that “climate action by the G20 has reached a turning point, with per capita emissions falling in 11 members, and renewable energy growing strongly” in 15.

Moreover, its analysis concludes that “there are strong indications that total global energy-related carbon dioxide emissions have stopped rising in 2014, the first such reversal in annual emissions growth in the industrial era, aside from periods of serious economic crisis.”
G20 performance is significant because the roster of the 19 member nations plus the European Union are a close if not exact match with a list of the world’s largest producers of greenhouse gases.
Collectively the G20 contributes about 85 percent of the world’s gross domestic product, conducts 80 percent of overall world trade, contains 64 percent of the world’s population – and, according to the report, creates 74 percent of global GHG output.

Their governments also provided, according to the other new analysis, subsidies for fossil-fuel production averaging $452 billion in 2013 and 2014 – or about four times the amount of production subsidies paid by all countries of the world to support expansion of renewable alternatives.
In 2009, the G20 leaders pledged to phase out “inefficient” fossil fuel subsidies. But a review of performance data by the UK’s Overseas Development Institute (ODI) and Oil Change International concludes that these were empty promises:
Their continued support for fossil fuel production marries bad economics with potentially disastrous consequences for the climate. In effect, governments are propping up the production of oil, gas and coal, most of which can never be used if the world is to avoid dangerous climate change. It is tantamount to G20 governments allowing fossil fuel producers to undermine national climate commitments, while paying them for the privilege.
Relying on the World Trade Organization’s definitions of subsidy, the ODI analysis found:
  • $78 billion in national subsidies delivered through direct spending and tax breaks.
  • $88 billion in public finance from state-owned banks and financial institutions.
  • $286 billion in investments by other state-owned business enterprises

Measuring policy results

Of the three organizations, Climate Transparency is a newer initiative and the least overtly activist in terms of a policy agenda. It was formed in 2014 as “an open consortium of organizations and initiatives with a shared mission to enhance assessments of action on climate change” and communicate “a comprehensive and picture of climate action for key influencers and decision makers.”

A principal source for this analysis was the Climate Action Tracker, a partnership of four research organizations that gathers performance data and assesses progress in 32 countries, responsible for about 80 percent of all global emissions, against the goal of holding global warming below the 2° Celsius target.

Climate Transparency’s declaration of a “turning point” begins with a trend line over the past 25 years in which global CO2 increased by 50 percent, with the trend line accelerating in the latter half of that period. Per capita emission rates were lower, because population grew faster than fossil fuel consumption, but still rose by 18 percent over the quarter-century.

Drawing on International Energy Agency data for 2007-2012, Climate Transparency found that per capita carbon emissions declined in the United States, Australia, Canada, Japan, Germany, Britain, South Africa, Italy, France and Mexico, as well as in the EU as a whole; they continued to increase in China and India – the most populous member nations – as well as in Saudi Arabia, South Korea, Russia, Argentina, Turkey, Brazil and Indonesia.

Where emissions are declining, Climate Transparency attributes the change in this way:
Renewable energy is continuing its strong growth worldwide. Costs have fallen sharply, and parity with traditional forms of energy is in sight, or already reached. Renewable energy sources are also helping to bring power to the millions of people who do not have access to electricity, where off grid renewable power can be installed faster and cheaper than a grid connection.
Climate legislation has been introduced in many countries and targets have been strengthened over time. Increasingly, there is knowledge sharing and collaboration over policies to promote renewable power, energy efficiency and carbon pricing. A substantial number of countries and regions have introduced carbon markets. Climate mitigation action is increasingly seen not as a cost, but a necessary investment in the future, which brings multiple other benefits.
Progress is not yet occurring fast enough to head off a global temperature rise above the 2° C danger mark, the report says; current per capita emissions worldwide average about 11 tons of CO2 equivalent per year, and that number needs to fall into the one- to three-ton range by 2050.
Still, it notes one more encouraging sign:
An important demonstration of the cumulative effect of these developments is that according to the International Energy Agency energy related emissions did not grow in 2014. Such a reversal of GHG emissions growth was previously seen only during periods of economic downturn. This time, it seems that climate policy is working. More ambition is needed, but there is room for hope and optimism.

Following the money

Although ODI and Oil Change International focused their analysis on the G20’s performance on fossil-fuel subsidies, the policy issues they emphasize are less about this weekend’s summit than the climate treaty talks in Paris that begin Nov. 30.

Claiming that its work “documents, for the first time, the scale and structure of fossil fuel production subsidies and the G20 countries,” the groups say the nearly half-trillion-dollar aggregate “supports a lose-lose scenario” that “calls into question the commitment of governments to an ambitious deal on climate change.”
They are pouring large amounts of finance into uneconomic, high-carbon assets that cannot be exploited without driving the planet far beyond the internationally agreed target of limiting global temperature increases to no more than 2° C. At the same time, they are diverting investment from economic low-carbon alternatives such as solar, wind and hydro-power… .
Several countries have scaled up their pledges to reduce greenhouse gas emissions, but continued subsidies for fossil fuel production raise serious concerns about these pledges and could undermine the prospects for an ambitious climate deal. As well as phasing out national subsidies, G20 governments have a tremendous opportunity to meet the climate challenge by shifting the investment of state-owned enterprises and public finance away from fossil fuel production, towards clean energy.
In the United States, the analysis counts “more than $20 billion in national fossil fuel production subsidies each year, despite calls from President Barack Obama to eliminate industry tax breaks.”
For comparison, it found $23 billion in direct subsidies by Russia, $9 billion by the UK, $5 billion by Australia and Brazil, and $3 billion in China.

However, additional payments by state-owned companies and banks often dwarfed those amounts: $50 billion for Russia, $42 billion for Brazil, and a whopping $77 billion for China.
In the aggregate, the report found that G20 nations provide $78 billion in national subsidies, $88 billion in public finance, and $286 billion in investment by state-owned enterprises to fossil-fuel producers.
One more discouraging snapshot: In the coal sector alone, the analysis found that producers in G20 member nations got almost twice as much public support as private investment — $19 billion versus $10 billion.

Sunday 15 November 2015

Good insight into the future impacts of Alzheimer’s Disease.

Alzheimer's: A Disease On Track to Bankrupt Medicare


     
Leading Alzheimer's researchers are optimistic that effective treatments to significantly slow or even halt the symptoms of this agonizing and ultimately fatal disease will be available within the next five years.

The hope springs from important breakthroughs on several fronts. Advances in high-powered imaging through PET (positron emission tomography) scans are giving researchers better diagnostic tools with which to view the brain. And a renewed interest in different brain proteins is providing greater clues as to which ones are responsible for kick-starting this devastating disease in the first place.

These discoveries have led to a flurry of clinical trials and studies now under way, and that's good news for Alzheimer's patients. Researchers say the work being done today could bring about a host of new drugs to treat the disease better and more effectively than anything currently on the market. These new therapies could potentially stop the progression of the disease before symptoms, like memory loss and confusion, ever start — something that's not possible with the drugs now being prescribed.

Says Dr. Marc Diamond, founding director of the Center for Alzheimer's and Neurodegenerative Diseases at the University of Texas Southwestern and one of the leading voices on Alzheimer's research: "It's an incredibly exciting time right now."

A devastating disease


To truly understand just how catastrophic an illness Alzheimer's is, consider that it is the only cause of death among the top 10 in the U.S. that can't yet be prevented, cured or even slowed. Someone diagnosed with cancer, heart disease or even HIV/AIDS has a better chance of surviving — and having a better quality of life while battling the disease — than a person diagnosed with Alzheimer's.
According to the Alzheimer's Association, there are now 5.3 million Americans age 65 and older living with the disease. The total direct cost to the U.S. economy of caring for those with Alzheimer's: a staggering $226 billion, with half being borne by Medicare.

Delaying the onset of the disease by just five years, research studies show, could decrease Medicare spending by 50 percent. That's an important point to consider, because economists forecast that unless something is done to cure or even slow the symptoms, the number of people with Alzheimer's will rise to 16 million by 2050 and cost the U.S. economy $1.1 trillion. The portion covered by Medicare will balloon to $589 billion.

Closer to home, the financial burden of caring for someone with Alzheimer's can be devastating. According to a recent study by the Annals of Internal Medicine, the cost of caring for a person with Alzheimer's in the last five years of life is $287,038.

That's far higher than the costs incurred for a person who died from cancer or heart disease. The reason: Alzheimer's patients need the kind of care at the end of their lives — bathing, dressing and eating — that's not covered by insurance. This puts a tremendous burden on a spouse or, in many cases, adult children who may be trying to save for their own retirement or have college tuitions to pay.
"This is clearly the underfunded and understudied problem of the 21st century."
One point that all the experts we spoke with agree on is that federal funding for Alzheimer's research needs to increase — and soon. Currently, just under $1 billion a year is allocated for Alzheimer's research. That's far less than the $5 billion spent on cancer or the $3 billion on HIV/AIDS research, according to the Alzheimer's Association.

"This is clearly the underfunded and understudied problem of the 21st century," says Dr. Bruce Miller, director of the Memory and Aging Center at the University of California, San Francisco. "We've made a lot of progress in therapies around heart disease, cancer and stroke, and we need to move faster in Alzheimer's research. If we can't find better therapies for an aging brain, as a society we will dramatically suffer."

A lack of effective drugs

The FDA-approved drugs now on the market and most widely prescribed to treat Alzheimer's — Aricept and Namenda — are helpful but limited, doctors say. "What's available now are symptomatic treatments that simply give a patient maybe six to 12 months of doing just a little bit better," says Dr. Reisa Sperling, a leading Alzheimer's researcher and professor of neurology at Harvard Medical School. Even the newest drug on the market — Namzaric — is basically a combination of two existing drugs and claims only to slow the worsening of symptoms for a while. Like Aricept and Namenda, Namzaric has no effect on stopping or preventing the underlying disease.

But now it seems like the focus — and promise — of Alzheimer's research is beginning to shift. For the past two decades the main target in research has been an influential brain protein called beta-amyloid. Over time this protein can build up outside the brain's neurons and form what's known as amyloid plaque. The hypothesis for decades has been that it's this plaque buildup that ultimately leads to Alzheimer's in certain patients.

As a result, the overwhelming focus in the field has been on beta-amyloid. "For the past 15 or 20 years, if a researcher was not studying beta-amyloid, the chances of getting funding or grant money was quite low," says Dr. Jim Sullivan, vice president of discovery for AbbVie, a pharmaceutical company involved in Alzheimer's research.

The problem with this singular approach is that, in patients with moderate to severe Alzheimer's symptoms, lowering beta-amyloid levels does not make a difference in the severity of the disease or its progression. Further complicating the picture is the fact that, thanks to the brain images now possible with PET scans, it has been proved that individuals can have significant levels of amyloid in their brain and not show signs of Alzheimer's or any other type of dementia.

Leading Alzheimer's researchers are optimistic that effective treatments to significantly slow or even halt the symptoms of this agonizing and ultimately fatal disease will be available within the next five years.

The hope springs from important breakthroughs on several fronts. Advances in high-powered imaging through PET (positron emission tomography) scans are giving researchers better diagnostic tools with which to view the brain. And a renewed interest in different brain proteins is providing greater clues as to which ones are responsible for kick-starting this devastating disease in the first place.

These discoveries have led to a flurry of clinical trials and studies now under way, and that's good news for Alzheimer's patients. Researchers say the work being done today could bring about a host of new drugs to treat the disease better and more effectively than anything currently on the market. These new therapies could potentially stop the progression of the disease before symptoms, like memory loss and confusion, ever start — something that's not possible with the drugs now being prescribed.
These findings have ignited renewed interest in other cognitive culprits; chief among them is another brain protein, called tau. Unlike beta-amyloid, which forms and builds up outside the neurons in the brain, tau develops inside the neurons. From there it can do its damage by traveling to neighboring cells and acting as a sort of virus that corrupts the normal protein of these other cells. For this reason, researchers believe tau may play an even more direct and influential role than beta-amyloid in the development of Alzheimer's and other forms of dementia.

Diamond of the University of Texas describes the relationship between these two proteins this way: "If [beta-amyloid] unlocks the barn door and let's the tau out, then tau is the horse that goes running off," he says. "It's the progression of tau as it moves through your brain that actually causes Alzheimer's dementia, but it's the [beta-amyloid] that sets you up to get that pathology."

Searching for a better treatment

If the past several decades were focused on developing drugs that might improve life for patients with symptoms of Alzheimer's, current research is all about arresting — or even preventing — the disease before the first symptoms ever appear. Says Miller of UC San Francisco: "We know now that prevention of this disease is feasible and something our field will conquer."

In other diseases, such as certain types of cancer or heart disease, genetic screenings are often the first line of defense. However, that approach is hotly debated when it comes to screening for Alzheimer's. "I don't think we should be screening for the presence of beta-amyloid in the general population until we have something effective to offer people," says Sperling.

In the case of individuals with a family history of Alzheimer's, the testing may be warranted, Miller says. But he adds it still leads to an uneasy choice. "There are those individuals who might argue that it's a person's right to know if they're going to get the disease," he says.

And then there are doctors who argue that giving people this information does not improve the quality of life but in fact worsens it, because there are no effective treatments to stop the disease, he adds.

In the meantime, multiple studies and trials involving both tau and beta-amyloid are now under way to figure out how to prevent Alzheimer's. On the tau front, pharmaceutical company AbbVie and C2N Diagnostics are in Phase 1 of a clinical trial to test a tau antibody in patients with progressive supranuclear palsy (PSP), a neurological disease closely related to Alzheimer's. Early next year, the company will start Phase 1 testing of the antibody with Alzheimer's patients. The goal, says Sullivan, is to slow down the progression of the disease by blocking the spread and accumulation of tau in the brain.
"Someone in the U.S. develops Alzheimer's every 67 seconds."
At Harvard, Sperling is the project leader for a clinical study that is exploring if lowering beta-amyloid buildup in otherwise healthy patients with no memory loss can prevent Alzheimer's from developing down the road. The so-called A4 study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) is a public/private partnership between the National Institutes of Health (NIH) and pharmaceutical company Eli Lilly and will include approximately 1,000 people ages 65 to 85 over the next three and a half years.

Half the group will receive the drug being tested, and half will get a placebo. Every six months, patients will undergo cognitive testing to see if there is any difference in their memory and recall. At three points during the study, they will have a brain PET scan to see if their amyloid buildup has changed.

"This is analogous to what we do with cholesterol, by trying to do things that keep it in check so that we can prevent heart attacks and strokes before they happen," Sperling says.

Whether it's through the tau protein or beta-amyloid, preventing Alzheimer's is the major focus of researchers today. "I think our best bet with Alzheimer's is to act before there are symptoms," she says. "Because by the time that happens, there's more than just a head full of amyloid. There's already loss of key neurons and brain shrinkage that we're not going to be able to bring back."
— By Susan Caminiti, special to CNBC.com

Wednesday 11 November 2015

Interesting info about the relationship between hearing aids and mental decline of elderly!

Hearing aids may slow mental decline in hard-of-hearing elderly 

                              
Employee of GN, the world's fourth largest maker of hearing aids, demonstrates the use of ReSound LiNX in Vienna
.
View photo
An employee of GN, the world's fourth largest maker of hearing aids, demonstrates the use of ReSound …
By Janice Neumann
(Reuters Health) - Seniors with hearing loss who use hearing aids may experience cognitive decline at a rate more like their peers without hearing trouble, according to a French study that followed thousands of seniors for 25 years.

Past research has shown a link between hearing loss and steeper cognitive decline in old age, but few have tracked that relationship over a quarter century.

“With a large sample size and 25 years of follow-up of participants, this study clearly confirms that hearing loss is associated with cognitive decline in older adults,” said the study’s lead author, Helene Amieva. “Using hearing aids attenuates cognitive decline in elders presenting with hearing loss.”
Amieva, a researcher at the University of Bordeaux in France, pointed out that about 30 percent of people age 65 and older have some degree of hearing loss and that’s true of 70 percent to 90 percent of those aged 85 and older.

“It is well known that individuals with hearing loss often experience depressive symptoms and social isolation,” Amieva said in an email.

To see if hearing loss contributes to cognitive decline with age, and if hearing aids might offset that effect, the researchers used data from a large, long-term study of people in France who were 65 and older and living at home, rather than in institutional settings, when they were first recruited in 1989-1990.

Amieva’s team focused on more than 3,700 people who answered questionnaires 12 times over 25 years and underwent psychological exams to assess their cognitive skills and mood. Of this group, 137 people reported at the outset that they had major hearing loss, another 1,139 had moderate hearing problems such as trouble following conversations with several people talking or in a noisy background and 2,394 had no hearing troubles.

Those with hearing loss were more likely to be men and less educated, to have depressive symptoms and more chronic diseases, and to be more dependent on others, the authors report in the Journal of the American Geriatrics Society.

Cognitive decline was measured with a 30-point questionnaire often used to screen for dementia, which includes questions such as what year it is and asks individuals to repeat simple phrases. The participants’ ability to perform activities of daily living well, and their degree of depressive symptoms were also assessed.

After accounting for age, gender and education, the researchers found there was a significant association between hearing loss and a lower score on the mental health screening, as well as greater cognitive decline over the 25-year period.

Overall, people with hearing loss scored lower for cognitive skills at the beginning of the study compared to the people without hearing loss.

But among those with hearing loss, people who used hearing aids experienced a rate of decline in cognitive skills that was more like those without any hearing loss. For participants with hearing problems who did not use hearing aids, the decline was steeper, translating to an extra 1.5 points of decline on a 30-point scale over 25 years.

“It is a significant decline, both from a clinical and statistical point of view,” Amieva said.
After adjusting for depressive symptoms, social networks, chronic diseases, dependency, psychotropic drug use and dementia, however, the differences in cognitive decline diminished, the authors note.

“One thought is when individuals do have hearing loss, what happens is they miss bits and pieces of information and so it isolates them,” said Thomas Zalewski of Bloomsburg University of Pennsylvania, who was not involved in the study. “So when people are isolated, they aren’t communicating as much and what happens is this vicious cycle.”

“They’re not engaged and we all know when we’re not engaged, we have this increase in cognitive decline,” he said.

The study team concludes that auditory rehabilitation programs should be considered for older people who can’t hear well. Such programs include listening and communication skills, as well as instruction in the use of hearing aids.

“These results underline the importance of addressing the problem of under-diagnosis and under-treatment of hearing loss in elderly adults,” Amieva told Reuters Health.

SOURCE: http://bit.ly/1RCnDHP Journal of the American Geriatrics Society, online October 20, 2015.

http://news.yahoo.com/hearing-aids-may-slow-mental-decline-hard-hearing-154245358.html

Monday 31 August 2015

Over 46 Million People Now Have Dementia Worldwide

136104625
Getty Images

Dementia is often caused by Alzheimer's Disease

More than 46 million people around the world suffer from dementia, according to a report released Tuesday.
The World Alzheimer Report, published byAlzheimer’s Disease International and King’s College London, says the number of people affected by dementia has increased quickly from the 35 million estimated in 2009, and researchers warn that number could double in the next 20 years.
Dementia is a collective term for progressive, degenerative brain syndromes affecting cognitive functions. Alzheimer’s disease is a common cause of dementia.
The report also noted that 58% of all people with dementia reside in developing countries. By 2050, 68% of those with dementia will be located in low and middle income countries, where services are limited and populations are aging quickly.
There is no cure for dementia.

Sunday 30 August 2015

Fat deposits in brain may hasten Alzheimer's disease

breakthrough in Alzheimer's research reveals that an abnormal build-up of fat droplets in the brain may cause or speed up the disease. The finding promises to open new avenues in the search for a cure or new treatments.
woman with dementia with carer
The study could prove to be a missing link in the field of Alzheimer's disease research.
The research, led by the Research Center of the University of Montreal Hospital (CRCHUM) in Canada, is published in the journal Cell Stem Cell.
The researchers note how, for the first time since 1906, when Dr. Alois Alzheimer first described the disease that takes his name, they found accumulations of fat droplets in the brains of patients who died of the disease. They have also identified the type of fat.
Initially, the team was trying to find out why the brain's stem cells - which normally repair brain damage - appear to be inactive in Alzheimer's disease.
They were astonished to find fat droplets near the stem cells in the brains of mice bred to develop a form of Alzheimer's disease.
First author and doctoral student Laura Hamilton says she and her colleagues realized that Alzheimer himself had noted the presence of fat build up in patients' brains after they died. This was dismissed and largely forgotten, however; at the time, the biochemistry of the fat was too complex to study.
According to the World Health Organization, there are 48 million people worldwide living with dementia - a general term for loss of memory and other mental abilities serious enough to interfere with daily life. Alzheimer's disease accounts for two-thirds of dementia cases.

Significant fat build up in brains of people who died of Alzheimer's disease

The team went on to compare the brains of nine patients who died from Alzheimer's disease with the brains of five people who did not die of the disease. They found significantly more fat droplets in the brains of the patients with Alzheimer's disease.
Fast facts about Alzheimer's disease
  • While its greatest known risk factor is age, Alzheimer's disease is not a normal part of aging
  • The most common early symptom is difficulty remembering newly learned information
  • Although current treatments cannot stop the disease progressing, they can slow symptoms for a while.
Then, using advanced mass spectrometry, the researchers identified the fat deposits to be triglycerides enriched with specific fatty acids, which can also be found in animal fats and vegetable oils.
The team believes the finding could prove to be a missing link in the field of Alzheimer's research.
Senior author Karl Fernandes, a CRCHUM researcher and professor at the University of Montreal, explains:
"We discovered that these fatty acids are produced by the brain, that they build up slowly with normal aging, but that the process is accelerated significantly in the presence of genes that predispose to Alzheimer's disease."
The researchers found that the brains of mice predisposed to the disease build up these fatty acid deposits at 2 months, which in human terms would be the early twenties.
"Therefore, we think that the build-up of fatty acids is not a consequence but rather a cause or accelerator of the disease," Prof. Fernandes says.
The team says inhibitor drugs that are already being tested for metabolic diseases such asobesity, can block the enzyme that produces these fatty acids and stop them accumulating. Tests on mice predisposed to the disease confirmed this. Prof. Fernandes concludes:
"The impact of this treatment on all the aspects of the disease is not yet known, but it significantly increased stem cell activity. This is very promising because stem cells play an important role in learning, memory and regeneration."
The risk of developing Alzheimer's disease doubles every 5 years after the age of 65. In line with this, a study that Medical News Today covered recently shows that the brain's ability to clear away a toxic protein fragment associated with the disease is much reduced in older people.